Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Circulation · 2023
DOI: 10.1161/circulationaha.123.064786 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation, 2023. Verfasst von Auke T Bergeman und 49 weiteren Autor:innen. Beteiligte Einrichtung: Heart Centre, Department of Cardiology (A.T.B., K.V.V.L., P.J.P., A.A.M.W., C.v.d.W.), Amsterdam UMC Location AMC, University of Amsterdam, The Nethe…. Hauptthemen laut MEDLINE: Tachycardia, Ventricular, Defibrillators, Implantable. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia. METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients. RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14–29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7–3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4–7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0–6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38–0.83]; P =0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31–0.77]; P =0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14–0.45]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart Centre, Department of Cardiology (A.T.B., K.V.V.L., P.J.P., A.A.M.W., C.v.d.W.), Amsterdam UMC Location AMC, University of Amsterdam, The Netherlands.
- Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, The Netherlands (A.T.B., K.V.V.L., P.J.P., A.A.M.W., C.v.d.W.).
- Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, Canada (D.K., S.F., S.S.).
- Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Divisions of Heart Rhythm Services and Pediatric Cardiology, Windland Smith Rice Genetic…
- Department of Cardiology, Royal Brompton Hospital, London, United Kingdom (F.R.y.N., J.T.).
- Department of Paediatric Cardiology, Vall d'Hebron University Hospital, Barcelona, Spain (F.R.y.N.).
ORCID-Profile: Isabelle Denjoy, Esther Zorio, Janneke A E Kammeraad, Puck J Peltenburg, Takeshi Aiba, Joseph Atallah, Fabrizio Drago, Ramon Brugada, Martin Borggrefe, Sally-Ann B Clur, Moniek G P J Cox, Andrew Davis, Santokh Dhillon, Susan P Etheridge, Kristina Haugaa, Minoru Horie, Christopher Johnsrude, Ulrich Krause, Martin J LaPage, Seiko Ohno, Vincent Probst, Jason D Roberts, Tomas Robyns, Frederic Sacher, Christopher Semsarian, Jonathan R Skinner, Terezia Tavacova, Svjetlana Tisma-Dupanovic, Jacob Tfelt-Hansen, Sing-Chien Yap, Prince J Kannankeril, Antoine Leenhardt, Shubhayan Sanatani, Michael J Ackerman, Arthur A M Wilde, Christian van der Werf
Zitieren
APA
Bergeman, A. T., Lieve, K. V. V., Kallas, D., Bos, J. M., Rosés I Noguer, F., Denjoy, I., Zorio, E., Kammeraad, J. A. E., Peltenburg, P. J., Tobert, K., Aiba, T., Atallah, J., Drago, F., Batra, A. S., Brugada, R., Borggrefe, M., Clur, S. B., Cox, M. G. P. J., Davis, A., …, & van der Werf, C. (2023). Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. https://doi.org/10.1161/circulationaha.123.064786
Vancouver
Bergeman AT, Lieve KVV, Kallas D, Bos JM, Rosés I Noguer F, Denjoy I, et al. Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. 2023. doi:10.1161/circulationaha.123.064786
BibTeX
@article{Bergeman2023,
author = {Bergeman, Auke T and Lieve, Krystien V V and Kallas, Dania and Bos, J Martijn and Rosés I Noguer, Ferran and Denjoy, Isabelle and Zorio, Esther and Kammeraad, Janneke A E and Peltenburg, Puck J and Tobert, Katie and Aiba, Takeshi and Atallah, Joseph and Drago, Fabrizio and Batra, Anjan S and Brugada, Ramon and Borggrefe, Martin and Clur, Sally-Ann B and Cox, Moniek G P J and Davis, Andrew and Dhillon, Santokh and Etheridge, Susan P and Fischbach, Peter and Franciosi, Sonia and Haugaa, Kristina and Horie, Minoru and Johnsrude, Christopher and Kane, Austin M and Krause, Ulrich and Kwok, Sit-Yee and LaPage, Martin J and Ohno, Seiko and Probst, Vincent and Roberts, Jason D and Robyns, Tomas and Sacher, Frederic and Semsarian, Christopher and Skinner, Jonathan R and Swan, Heikki and Tavacova, Terezia and Tisma-Dupanovic, Svjetlana and Tfelt-Hansen, Jacob and Yap, Sing-Chien and Kannankeril, Prince J and Leenhardt, Antoine and Till, Janice and Sanatani, Shubhayan and Tanck, Michael W T and Ackerman, Michael J and Wilde, Arthur A M and van der Werf, Christian},
title = {Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia},
journal = {Circulation},
year = {2023},
doi = {10.1161/circulationaha.123.064786}
}
EUVIMED